Changes of myocardial lipidomics profiling in a rat model of diabetic cardiomyopathy using UPLC/Q-TOF/MS analysis

Diabetology and Metabolic Syndrome

Volumn 9, Issue 1, 2017, Pages

  Dong, Shifen ^a   Zhang, Rong ^a   Liang, Yaoyue ^a   Shi, Jiachen ^a   Li, Jiajia ^a   Shang, Fei ^b   Mao, Xuezhou ^c   Sun, Jianning ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^c SANOFI   (France)

Author keywords

Diabetic cardiomyopathy; Lipidomics profiling; Myocardial tissue; UPLC Q TOF MS analysis

Indexed keywords

GLUCOSE; LIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DISCRIMINANT ANALYSIS; DOWN REGULATION; GLUCOSE BLOOD LEVEL; HEART; HEART CATHETERIZATION; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE PRESSURE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LIPID BLOOD LEVEL; LIPIDOMICS; MALE; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROPHOTOMETRY; UPREGULATION;

EID: 85025078604     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-017-0249-6     Document Type: Article

References (41)

1. Overgaard AJ, Weir JM, De Souza DP, Tull D, Haase C, Meikle PJ, et al. Lipidomic and metabolomic characterization of a genetically modified mouse model of the early stages of human type 1 diabetes pathogenesis. Metabolomics. 2016;12:13.
2. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006;12:62-6.
3. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-90.
4. Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet. 2011;377:529-32.
5. Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab. 2007;9:767-80.
6. Wende AR, Symons JD, Abel ED. Mechanisms of lipotoxicity in the cardiovascular system. Curr Hypertens Rep. 2012;14:517-31.
7. Loffroy R, Bernard S, Serusclat A, Boussel L, Bonnefoy E, D'Athis P, et al. Noninvasive assessment of the prevalence and characteristics of coronary atherosclerotic plaques by multidetector computed tomography in asymptomatic type 2 diabetic patients at high risk of significant coronary artery disease: a preliminary study. Arch Cardiovasc Dis. 2009;102:607-15.
8. Trachanas K, Sideris S, Aggeli C, Poulidakis E, Gatzoulis K, Tousoulis D, et al. Diabetic cardiomyopathy: from pathophysiology to treatment. Hellenic J Cardiol. 2014;55:411-21.
9. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699-703.
10. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121:748-57.
11. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol. 2011;48:173-81.
12. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013;18:149-66.
13. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006;98:596-605.
14. Chavali V, Tyagi SC, Mishra PK. Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes. 2013;6:151-60.
15. D'Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling in cardiac lipotoxicity. Biochim Biophys Acta. 2016;1860:1513-24.
16. Kralik PM, Ye G, Metreveli NS, Shem X, Epstein PN. Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. Cardiovasc Toxicol. 2005;5:285-92.
17. Dong SF, Hong Y, Liu M, Hao YZ, Yu HS, Liu Y, et al. Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. Eur J Pharmacol. 2011;660:368-74.
18. Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z, et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 2013;123:1262-74.
19. Brugger B. Lipidomics: analysis of the lipid composition of cells and subcellular organelles by electrospray ionization mass spectrometry. Annu Rev Biochem. 2014;83:79-98.
20. Rolim AE, Henrique-Araujo R, Ferraz EG, de Araujo Alves Dultra FK, Fernandez LG. Lipidomics in the study of lipid metabolism: current perspectives in the omic sciences. Gene. 2015;554:131-9.
21. Gudbjarnason S. Dynamics of n-3 and n-6 fatty acids in phospholipids of heart muscle. J Intern Med Suppl. 1989;731:117-28.
22. Benediktsdottir VE, Curvers J, Gudbjarnason S. Time course of alterations in phospholipid fatty acids and number of beta-adrenoceptors in the rat heart during adrenergic stimulation in vivo. J Mol Cell Cardiol. 1999;31:1105-15.
23. Skuladottir GV, Schioth HB, Gudbjarnason S. Polyunsaturated fatty acids in heart muscle and alpha 1-adrenoceptor binding properties. Biochim Biophys Acta. 1993;1178:49-54.
24. Park TS, Goldberg IJ. Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin. 2012;8:633-41.
25. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res. 2010;51:3299-305.
26. Kanno K, Wu MK, Scapa EF, Roderick SL, Cohen DE. Structure and function of phosphatidylcholine transfer protein (PC-TP)/StarD2. Biochim Biophys Acta. 2007;1771:654-62.
27. Pugsley MK, Authier S, Curtis MJ. Principles of safety pharmacology. Br J Pharmacol. 2008;154:1382-99.
28. Lamari F, Mochel F, Sedel F, Saudubray JM. Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases. J Inherit Metab Dis. 2013;36:411-25.
29. Jakobsson A, Westerberg R, Jacobsson A. Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog Lipid Res. 2006;45:237-49.
30. Gomase VS, Tagore S, Kale KV. Microarray: an approach for current drug targets. Curr Drug Metab. 2008;9:221-31.
31. Novak F, Tvrzicka E, Hamplova B, Kolar F, Novakova O. Postnatal development of phospholipids and their fatty acid profile in rat heart. Mol Cell Biochem. 2006;293:23-33.
32. Slater-Jefferies JL, Hoile SP, Lillycrop KA, Townsend PA, Hanson MA, Burdge GC. Effect of sex and dietary fat intake on the fatty acid composition of phospholipids and triacylglycerol in rat heart. Prostaglandins Leukot Essent Fatty Acids. 2010;83:219-23.
33. Wahjudi PN, Yee JK, Martinez SR, Zhang J, Teitell M, Nikolaenko L, et al. Turnover of nonessential fatty acids in cardiolipin from the rat heart. J Lipid Res. 2011;52:2226-33.
34. Jeckel KM, Miller KE, Chicco AJ, Chapman PL, Mulligan CM, Falcone PH, et al. The role of dietary fatty acids in predicting myocardial structure in fat-fed rats. Lipids in health and disease. 2011;10:92.
35. Kien CL, Bunn JY, Poynter ME, Stevens R, Bain J, Ikayeva O, et al. A lipidomics analysis of the relationship between dietary fatty acid composition and insulin sensitivity in young adults. Diabetes. 2013;62:1054-63.
36. Shintu L, Baudoin R, Navratil V, Prot JM, Pontoizeau C, Defernez M, et al. Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. Anal Chem. 2012;84:1840-8.
37. Santos JL, Salemi VM, Picard MH, Mady C, Coelho OR. Subclinical regional left ventricular dysfunction in obese patients with and without hypertension or hypertrophy. Obesity. 2011;19:1296-303.
38. Ramirez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Ruperez FJ, et al. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol. 2013;12:172.
39. Tepsic V, Ristic V, Ristic D, Vasiljevic N, Pecelj-Gec M. Heart phospholipid content and fatty acid composition in the rat after feeding different lipid supplemented diets. Physiol Res Acad Sci Bohemoslov. 1998;47:413-8.
40. Van de Velde M, DeWolff M, Leather HA, Wouters PF. Effects of lipids on the functional and metabolic recovery from global myocardial stunning in isolated rabbit hearts. Cardiovasc Res. 2000;48:129-37.
41. Demarco VG, Ford DA, Henriksen EJ, Aroor AR, Johnson MS, Habibi J, et al. Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology. 2013;154:159-71.